Jackson Creek Investment Advisors LLC Takes Position in Catalyst Pharmaceuticals, Inc. $CPRX

Jackson Creek Investment Advisors LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 19,824 shares of the biopharmaceutical company’s stock, valued at approximately $463,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Deerfield Management Company L.P. grew its position in Catalyst Pharmaceuticals by 72.8% during the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after buying an additional 2,095,291 shares during the period. Fundsmith LLP lifted its position in shares of Catalyst Pharmaceuticals by 24.2% during the 3rd quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after acquiring an additional 654,721 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Catalyst Pharmaceuticals by 11.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after acquiring an additional 333,100 shares during the period. American Century Companies Inc. lifted its position in shares of Catalyst Pharmaceuticals by 43.8% during the 3rd quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock valued at $49,805,000 after acquiring an additional 770,198 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Catalyst Pharmaceuticals by 28.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,458,169 shares of the biopharmaceutical company’s stock valued at $48,424,000 after acquiring an additional 550,648 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on CPRX shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Citigroup downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $35.00 to $31.50 in a research report on Friday, May 8th. Oppenheimer downgraded shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Robert W. Baird downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.17.

Catalyst Pharmaceuticals Trading Down 0.0%

Shares of CPRX opened at $31.32 on Thursday. The stock has a market cap of $3.83 billion, a P/E ratio of 18.00, a PEG ratio of 0.91 and a beta of 0.72. The company has a 50-day moving average of $27.29 and a two-hundred day moving average of $24.92. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $32.56.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).